Landos to begin early-stage trial of autoimmune disease drug in Q4, shares up

Landos Biopharma

15/09/2021 19:33

** Shares of biotech company  LABP.O  up 13.2% at $15.65
    ** Company says it will present preclinical data of its oral
drug candidate, LABP-104, for systemic lupus erythematosus (SLE)
at an industry meeting on Nov. 6 
    ** SLE is an autoimmune disease, causing widespread
inflammation and tissue damage in affected organs such as
kidneys, lungs, and joints 
    ** Co to highlight data showing its drug increased the
function of a type of cells linked to lupus and decreased kidney
inflammation  urn:newsml:reuters.com:*:nGNX5Dv4nD
    ** Co expects to enter a Phase 1 clinical study of LABP-104
for lupus during Q4
    ** Stock up 30.4% since market debut in February

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))